首页> 外文期刊>International Immunology >Missense mutations in SH2D1A identified in patients with X-linked lymphoproliferative disease differentially affect the expression and function of SAP
【24h】

Missense mutations in SH2D1A identified in patients with X-linked lymphoproliferative disease differentially affect the expression and function of SAP

机译:X连锁淋巴组织增生性疾病患者中SH2D1A的错义突变差异影响SAP的表达和功能

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

X-linked lymphoproliferative disease (XLP) is an immunodeficiency resulting from mutations in SH2D1A, which encodes signalling lymphocytic activation molecule (SLAM)-associated protein (SAP). In addition to SLAM, SAP associates with several other cell-surface receptors including 2B4 (CD244), Ly9 (CD229), CD84 and NTB-A. SAP contains a single src-homology-2 domain and acts as an intracellular adaptor protein by recruiting the protein tyrosine kinase FynT to the cytoplasmic domains of some of these receptors, which results in the initiation of specific downstream signal transduction pathways. XLP is likely to result from perturbed signalling through one or more of these SAP-associating receptors. In this study, we identified missense (Y54C, I84T and F87S) and insertion (fs82 → X103) mutations in four different kindreds affected by XLP. Each mutation dramatically reduced the half-life of SAP, thus diminishing its expression in primary lymphocytes as well as in transfected cell lines. Interestingly, although the Y54C and F87S mutations compromised the ability of SAP to associate with different receptors, the I84T mutation had no effect on the ability of SAP to bind SLAM, CD84 or 2B4. However, signalling downstream of SLAM was reduced in the presence of SAP bearing the I84T mutation. These findings indicate that, irrespective of the type of mutation, signalling through SAP-associating receptors in XLP can be impaired by reducing the expression of SAP, the ability of SAP to bind surface receptors and/or its ability to activate signal transduction downstream of the SLAM–SAP complex.
机译:X连锁淋巴细胞增生性疾病(XLP)是由SH2D1A中的突变导致的免疫缺陷,该突变编码信号转导的淋巴细胞活化分子(SLAM)相关蛋白(SAP)。除了SLAM,SAP还与其他几种细胞表面受体相关,包括2B4(CD244),Ly9(CD229),CD84和NTB-A。 SAP包含单个src-homology-2结构域,并通过将蛋白酪氨酸激酶FynT募集到这些受体中某些受体的胞质域中而充当细胞内衔接蛋白,从而导致特定下游信号转导途径的启动。 XLP可能是由于通过这些SAP相关受体中的一种或多种干扰信号所致。在这项研究中,我们鉴定了四种受XLP影响的亲属的错义(Y54C,I84T和F87S)和插入(fs82→X103)突变。每种突变均会显着降低SAP的半衰期,从而降低其在原代淋巴细胞以及转染细胞系中的表达。有趣的是,尽管Y54C和F87S突变损害了SAP与不同受体结合的能力,但I84T突变对SAP结合SLAM,CD84或2B4的能力没有影响。但是,在存在I84T突变的SAP存在下,SLAM下游的信号传导减少。这些发现表明,不管突变的类型如何,通过降低SAP的表达,SAP结合表面受体的能力和/或其激活下游信号转导的能力,均可削弱通过XLP中SAP相关受体的信号传导。 SLAM–SAP复合体。

著录项

  • 来源
    《International Immunology》 |2006年第7期|1055-1065|共11页
  • 作者单位

    Lymphocyte Differentiation Centenary Institute for Cancer Medicine and Cell Biology Locked Bag No. 6 Newtown New South Wales 2042 Australia;

    Department of Experimental Medicine University of Sydney Sydney New South Wales Australia;

    Pediatric Hematology John Hunter Hospital Newcastle New South Wales Australia;

    Division of Pediatric Oncology Children's Hospital of Philadelphia PA 19104 USA;

    Present address: Garvan Institute of Medical Research 384 Victoria St Darlinghurst New South Wales 2042 Australia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号